Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Metastatic or Locally Advanced Renal Cell Carcinoma on Hemodialysis
NCT05241561Phase 2Not yet recruiting
- Sponsor
- CHU de Besançon
- Start
- Jun 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in renal cell carcinoma (RCC), sponsored by CHU de Besançon. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05241561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241561.